US45175G1085 - Common Stock
IKENA ONCOLOGY INC
NASDAQ:IKNA (7/1/2024, 7:00:02 PM)
After market: 1.65 0 (0%)1.65
0 (0%)
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed, and biomarker driven therapies for cancer patients. The company is headquartered in Boston, Massachusetts and currently employs 57 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company’s lead targeted oncology program, IK-930, is a TEAD1 selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company’s additional research spans other targets in the Hippo pathway, as well as the RAS signaling pathway, including developing IK-595, a novel MEK-RAF inhibitor. Additionally, IK-175, an aryl hydrocarbon receptor (AHR) antagonist, is being developed in collaboration with Bristol Myers Squibb. The company also offers clinical programs, including PY314 and PY159, targeting TREM2 and TREM1 respectively, and are designed to selectively deplete and in some cases reprogram certain tumor-associated macrophages responsible for immunosuppression.
IKENA ONCOLOGY INC
50 Northern Ave.
Boston MASSACHUSETTS 02210
P: 18573438292
CEO: Mark Manfredi
Employees: 57
Website: https://www.ikenaoncology.com
It's time to start the day with a breakdown of the biggest pre-market stock movers traders are going to want to watch on Wednesday morning!
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date ...
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date ...
IKNA stock results show that Ikena Oncology beat analyst estimates for earnings per share the first quarter of 2024.
Here you can normally see the latest stock twits on IKNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: